MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Early findings from the Rheos™ Trial show a significant reduction in blood pressure in patients with drug-resistant hypertension who have a systolic blood pressure of 160 mmHg or greater. The ongoing study is assessing the safety and clinical efficacy of the Rheos™ Baroreflex Hypertension Therapy™ System, an implantable device for the treatment of hypertension in patients who cannot control their blood pressure with medications and lifestyle modifications. CVRx, a private medical device company in Minneapolis, developed the Rheos System. Dr. John Bisognano of the University of Rochester, Rochester, N.Y., and a lead investigator of the Rheos Trial, presented the study findings today at the American Heart Association 2006 Scientific Sessions in Chicago.
